Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus

Clinical Rheumatology

Volumn 18, Issue 3, 1999, Pages 238-240

  Sherer, Y ^a   Levy, Y ^a   Shoenfeld, Y ^a  

^a Department of Medicine B ^*

Author keywords

Intravenous immunoglobulin; Myocarditis; Systemic lupus erythematosus; Vasculitis

Indexed keywords

IMMUNOGLOBULIN; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DOSE RESPONSE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYOCARDITIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYOCARDITIS; PREDNISONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032983315     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670050091     Document Type: Article

References (23)

1. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.
2. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R. Long term I.V.Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-8.
3. Puddu P, De Pita O, Ruffelli M, Bellucci AM, Girardelli CR, Galeazzi M, Marcolongo R. Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:704-8.
4. Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997;6:408-11.
5. Ruiz-Valverde MP, Segarra A, Tovar JL, Piera L. Treatment of systemic lupus erythematosus-associated thrombocytopenia with intravenous gamma globulin [letter]. Nephron 1994;67:500-1.
6. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10:391-3.
7. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988;319:817-23.
8. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579-87.
9. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985;110:1257-65.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Wilson VE, Eck SL, Bates ER. Evaluation and treatment of acute myocardial infarction complicating systemic lupus erythematosus. Chest 1992;101:420-4.
12. Przybojewski JZ, Botha D, Klopper JF, van der Walt JJ, Tiedt FA. Systemic lupus erythematosus with coronary vasculitis and massive myocardial infarction. A case report. S Afr Med J 1986;69:765-8.
13. Frustaci A, Gentiloni N, Caldarulo M. Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest 1996;109:282-4.
14. MacLean C, Brahn E. Systemic lupus erythematosus: calciphylaxis induced cardiomyopathy. J Rheumatol 1995;22:177-9.
15. Disla E, Rhim HR, Reddy A, Ramaprasad S, Taranta A. Reversible cardiogenic shock in a patient with lupus myocarditis [letter]. J Rheumatol 1993;20:2174.
16. Cuny C, Eicher JC, Collet E, Chatard C, Chauffert B, Lorcerie B, et al. Dilated cardiomyopathy disclosing dermatopolymyositis. Ann Cardiol Angiol 1993;42:155-8.
17. Leung DY. Kawasaki disease. Curr Opin Rheumatol 1993;5:41-50.
18. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994;89:252-7.
19. Koehler PJ, Koudstaal J. Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenytoin [letter]. J Neurol 1996;243:366-7.
20. Ballow M. Mechanisms of action of intravenous immunoglobulin: clinical implications in autoimmune and inflammatory diseases. In: Kazatchkine MD, Morell A, editors. Intravenous immunoglobulin research and therapy. New York: Parthenon, 1996:123-8.
21. Krause I, Blank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol 1995;22:1068-74.
22. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993;69:97-102.
23. Evans M, Abdou NI. In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by antiidiotypic antibody of pooled human intravenous immune globulin. Lupus 1993;2:371-5.